In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: Application to schizophrenia

Neuroscience and Biobehavioral Reviews

Volumn 51, Issue , 2015, Pages 276-295

  Wijtenburg, S Andrea ^a   Yang, Shaolin ^b,c   Fischer, Bernard A ^a,f   Rowland, Laura M ^a,d,e  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c University of Illinois at Chicago   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

GABA; Glutamate; Glutathione; Magnetic resonance spectroscopy; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; BIOLOGICAL MARKER; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; GLYCINE; N ACETYLASPARTYLGLUTAMIC ACID; NEUROLEPTIC AGENT; NEUROTRANSMITTER; SERINE;

BRAIN LEVEL; DRUG EFFECT; FIRST DEGREE RELATIVE; HIGH RISK POPULATION; HUMAN; IN VIVO STUDY; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SCHIZOPHRENIA; ANIMAL; BRAIN; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES;

ANIMALS; BRAIN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; SCHIZOPHRENIA;

EID: 84922965702     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2015.01.007     Document Type: Review

References (186)

1. Ahn K., Gil R., Seibyl J., Sewell R.A., D'Souza D.C. Probing GABA receptor function in schizophrenia with iomazenil. Neuropsychopharmacology 2011, 36:677-683.
2. Aoyama N., Theberge J., Drost D.J., Manchanda R., Northcott S., Neufeld R.W., Menon R.S., Rajakumar N., Pavlosky W.F., Densmore M., Schaefer B., Williamson P.C. Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br. J. Psychiatry 2011, 198:448-456.
3. Ballesteros A., Jiang P., Summerfelt A., Du X., Chiappelli J., O'Donnell P., Kochunov P., Hong L.E. No evidence of exogenous origin for the abnormal glutathione redox state in schizophrenia. Schizophr. Res. 2013, 146:184-189.
4. Bardaweel S.K., Alzweiri M., Ishaqat A.A. d-Serine in neurobiology: CNS neurotransmission and neuromodulation. Can. J. Neurol. Sci. 2014, 41:164-176.
5. Behar K.L., Ogino T. Characterization of macromolecule resonances in the 1H NMR spectrum of rat brain. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 1993, 30:38-44.
6. 1H NMR spectra of human brain. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 1994, 32:294-302.
7. Beneyto M., Kristiansen L.V., Oni-Orisan A., McCullumsmith R.E., Meador-Woodruff J.H. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007, 32:1888-1902.
8. Beneyto M., Lewis D.A. Insights into the neurodevelopmental origin of schizophrenia from postmortem studies of prefrontal cortical circuitry. Int. J. Dev. Neurosci. 2011, 29:295-304.
9. Berger G.E., Wood S.J., Ross M., Hamer C.A., Wellard R.M., Pell G., Phillips L., Nelson B., Amminger G.P., Yung A.R., Jackson G., Velakoulis D., Pantelis C., Manji H., McGorry P.D. Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. Curr. Pharm. Des. 2012, 18:570-575.
10. Bergeron R., Coyle J.T. NAAG, NMDA receptor and psychosis. Curr. Med. Chem. 2012, 19:1360-1364.
11. Bogner W., Gruber S., Doelken M., Stadlbauer A., Ganslandt O., Boettcher U., Trattnig S., Doerfler A., Stefan H., Hammen T. In vivo quantification of intracerebral GABA by single-voxel (1)H MRS-How reproducible are the results?. Eur. J. Radiol. 2010, 73:526-531.
12. Bottomley P.A. Spatial localization in NMR spectroscopy in vivo. Ann. N. Y. Acad. Sci. 1987, 508:333-348.
13. Brosnan J.T., Brosnan M.E. Glutamate: a truly functional amino acid. Amino Acids 2013, 45:413-418.
14. Brouwer A., Luykx J.J., van Boxmeer L., Bakker S.C., Kahn R.S. NMDA-receptor coagonists in serum, plasma, and cerebrospinal fluid of schizophrenia patients: a meta-analysis of case-control studies. Neurosci. Biobehav. Rev. 2013, 37:1587-1596.
15. Brown M.A., Semelka R.C. MRI: Basic Principles and Applications 2010, Wiley-Blackwell/John Wiley & Sons, Hoboken, NJ. 4th ed.
16. Brugger S., Davis J.M., Leucht S., Stone J.M. Proton magnetic resonance spectroscopy and illness stage in schizophrenia - a systematic review and meta-analysis. Biol. Psychiatry 2011, 69:495-503.
17. Bustillo J.R., Chen H., Jones T., Lemke N., Abbott C., Qualls C., Canive J., Gasparovic C. Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3T. JAMA Psychiatry 2014, 71:265-272.
18. 1H MRS at 4Tesla in minimally treated early schizophrenia. Mol. Psychiatry 2010, 15:629-636.
19. Calcia M.A., Madeira C., Alheira F.V., Silva T.C., Tannos F.M., Vargas-Lopes C., Goldenstein N., Brasil M.A., Ferreira S.T., Panizzutti R. Plasma levels of d-serine in Brazilian individuals with schizophrenia. Schizophr. Res. 2012, 142:83-87.
20. Cavassila S., Deval S., Huegen C., van Ormondt D., Graveron-Demilly D. Cramer-Rao bounds: an evaluation tool for quantitation. NMR Biomed. 2001, 14:278-283.
21. Chang L., Friedman J., Ernst T., Zhong K., Tsopelas N.D., Davis K. Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. Biol. Psychiatry 2007, 62:1396-1404.
22. Chang L., Jiang C.S., Ernst T. Effects of age and sex on brain glutamate and other metabolites. Magn. Reson. Imaging 2009, 27:142-145.
23. 1H-MRS in vivo at 3.0T. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 2008, 59:59-64.
24. 1H-MRS) at 7Tesla. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 2009, 62:1042-1046.
25. Choi C., Douglas D., Hawesa H., Jindal A., Storey C., Dimitrov I. Measurement of glycine in human prefrontal brain by point-resolved spectroscopy at 7.0Tesla in vivo. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 2009, 62:1305-1310.
26. Cioffi C.L. Modulation of NMDA receptor function as a treatment for schizophrenia. Bioorg. Med. Chem. Lett. 2013, 23:5034-5044.
27. Coyle J.T., Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology 2004, 174:32-38.
28. Danbolt N.C. Glutamate uptake. Progr. Neurobiol. 2001, 65:1-105.
29. Danielsen E.R., Ross B.D. Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases 1999, Marcel Dekker, Inc., New York.
30. De Graaf R.A. In vivo NMR Spectroscopy: Principles and Techniques 2007, John Wiley & Sons, Chichester, West Sussex, England/Hoboken, NJ. second ed.
31. 1H-MRS imaging study. Int. J. Neuropsychopharmacol. 2013, 16:471-475.
32. de la Fuente-Sandoval C., Leon-Ortiz P., Azcarraga M., Stephano S., Favila R., Diaz-Galvis L., Alvarado-Alanis P., Ramirez-Bermudez J., Graff-Guerrero A. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry 2013, 70:1057-1066.
33. de la Fuente-Sandoval C., Leon-Ortiz P., Favila R., Stephano S., Mamo D., Ramirez-Bermudez J., Graff-Guerrero A. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 2011, 36:1781-1791.
34. 1H NMR spectroscopy of the human brain at 9.4T: initial results. J. Magn. Reson. 2010, 206:74-80.
35. Deng C., Huang X.F. Increased density of GABAA receptors in the superior temporal gyrus in schizophrenia. Exp. Brain Res. 2006, 168:587-590.
36. Do K.Q., Trabesinger A.H., Kirsten-Kruger M., Lauer C.J., Dydak U., Hell D., Holsboer F., Boesiger P., Cuenod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci. 2000, 12:3721-3728.
37. Dringen R. Metabolism and functions of glutathione in brain. Progr. Neurobiol. 2000, 62:649-671.
38. Drost D.J., Riddle W.R., Clarke G.D. Proton magnetic resonance spectroscopy in the brain: report of AAPM MR Task Group #9. Med. Phys. 2002, 29:2177-2197.
39. Duarte J.M., Gruetter R. Glutamatergic and GABAergic energy metabolism measured in the rat brain by (13) C NMR spectroscopy at 14.1T. J. Neurochem. 2013, 126:579-590.
40. Edden R.A., Barker P.B. Spatial effects in the detection of gamma-aminobutyric acid: improved sensitivity at high fields using inner volume saturation. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 2007, 58:1276-1282.
41. Edden R.A., Pomper M.G., Barker P.B. In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3Tesla. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 2007, 57:977-982.
42. Egerton A., Brugger S., Raffin M., Barker G.J., Lythgoe D.J., McGuire P.K., Stone J.M. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology 2012, 37:2515-2521.
43. Egerton A., Fusar-Poli P., Stone J.M. Glutamate and psychosis risk. Curr. Pharm. Des. 2012, 18:466-478.
44. Ermilov M., Gelfin E., Levin R., Lichtenberg P., Hashimoto K., Javitt D.C., Heresco-Levy U. A pilot double-blind comparison of d-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia. Schizophr. Res. 2013, 150:604-605.
45. Ernst T., Kreis R., Ross B.D. Absolute quantitation of water and metabolites in the human brain. I. Compartments and Water. J. Magn. Reson. 1993, 102:1-8.
46. Evans C.J., McGonigle D.J., Edden R.A. Diurnal stability of gamma-aminobutyric acid concentration in visual and sensorimotor cortex. J. Magn. Reson. Imaging 2010, 31:204-209.
47. Farber N.B., Newcomer J.W., Olney J.W. The glutamate synapse in neuropsychiatric disorders, focus on schizophrenia and Alzheimer's disease. Progr. Brain Res. 1998, 116:421-437.
48. Flatow J., Buckley P., Miller B.J. Meta-analysis of oxidative stress in schizophrenia. Biol. Psychiatry 2013, 74:400-409.
49. Frahm J., Merbolt J., Hanicke W. Localized proton spectroscopy using stimulated echoes. J. Magn. Reson. 1987, 72:502-508.
50. Furukawa H., Gouaux E. Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core. EMBO J. 2003, 22:2873-2885.
51. Fusar-Poli P., Bonoldi I., Yung A.R., Borgwardt S., Kempton M.J., Valmaggia L., Barale F., Caverzasi E., McGuire P. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch. Gen. Psychiatry 2012, 69:220-229.
52. Fusar-Poli P., Stone J.M., Broome M.R., Valli I., Mechelli A., McLean M.A., Lythgoe D.J., O'Gorman R.L., Barker G.J., McGuire P.K. Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. Arch. Gen. Psychiatry 2011, 68:881-890.
53. 1H MRS in human brain at 7T. Magma 2009, 22:1-4.
54. Gao F., Edden R.A., Li M., Puts N.A., Wang G., Liu C., Zhao B., Wang H., Bai X., Zhao C., Wang X., Barker P.B. Edited magnetic resonance spectroscopy detects an age-related decline in brain GABA levels. Neuroimage 2013, 78:75-82.
55. Gasparovic C., Song T., Devier D., Bockholt H.J., Caprihan A., Mullins P.G., Posse S., Jung R.E., Morrison L.A. Use of tissue water as a concentration reference for proton spectroscopic imaging. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 2006, 55:1219-1226.
56. Gawryluk J.W., Wang J.F., Andreazza A.C., Shao L., Yatham L.N., Young L.T. Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. Int. J. Neuropsychopharmacol. 2011, 14:1069-1074.
57. Geramita M., van der Veen J.W., Barnett A.S., Savostyanova A.A., Shen J., Weinberger D.R., Marenco S. Reproducibility of prefrontal gamma-aminobutyric acid measurements with J-edited spectroscopy. NMR Biomed. 2011, 24:1089-1098.
58. Ghose S., Chin R., Gallegos A., Roberts R., Coyle J., Tamminga C. Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia. Schizophr. Res. 2009, 111:131-137.
59. Gideon P., Rosenbaum S., Sperling B., Petersen P. MR-visible brain water content in human acute stroke. Magn. Reson. Imaging 1999, 17:301-304.
60. Goddard A.W., Mason G.F., Appel M., Rothman D.L., Gueorguieva R., Behar K.L., Krystal J.H. Impaired GABA neuronal response to acute benzodiazepine administration in panic disorder. Am. J. Psychiatry 2004, 161:2186-2193.
61. Goto N., Yoshimura R., Kakeda S., Moriya J., Hori H., Hayashi K., Ikenouchi-Sugita A., Nakano-Umene W., Katsuki A., Nishimura J., Korogi Y., Nakamura J. No alterations of brain GABA after 6 months of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia. Progr. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:1480-1483.
62. Goto N., Yoshimura R., Kakeda S., Nishimura J., Moriya J., Hayashi K., Katsuki A., Hori H., Umene-Nakano W., Ikenouchi-Sugita A., Korogi Y., Nakamura J. Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia. Neuropsychiatr. Dis. Treat. 2012, 8:119-122.
63. 1H MRS of the human brain at 3T: quantification of the metabolite signals using two approaches to account for macromolecular signal contributions. NMR Biomed. 2008, 21:507-517.
64. Govindaraju V., Young K., Maudsley A.A. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000, 13:129-153.
65. Gruber S., Pinker K., Riederer F., Chmelik M., Stadlbauer A., Bittsansky M., Mlynarik V., Frey R., Serles W., Bodamer O., Moser E. Metabolic changes in the normal ageing brain: consistent findings from short and long echo time proton spectroscopy. Eur. J. Radiol. 2008, 68:320-327.
66. 1H NMR spectra with increased magnetic field strength. J. Magn. Reson. 1998, 135:260-264.
67. Haacke E.M., Brown R.W., Thompson M.R., Venkatesan R. Magnetic Resonance Imaging: Physical Principles and Sequence Design 1999, Wiley, New York.
68. Hancu I., Port J. The case of the missing glutamine. NMR Biomed. 2011, 24:529-535.
69. Hashimoto K. Glycine transporter-1: a new potential therapeutic target for schizophrenia. Curr. Pharm. Des. 2011, 17:112-120.
70. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., Nakazato M., Kumakiri C., Okada S., Hasegawa H., Imai K., Iyo M. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 2003, 60:572-576.
71. Hashimoto K., Malchow B., Falkai P., Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263:367-377.
72. Hashimoto T., Arion D., Unger T., Maldonado-Aviles J.G., Morris H.M., Volk D.W., Mirnics K., Lewis D.A. Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry 2008, 13:147-161.
73. Heresco-Levy U., Javitt D.C. Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr. Res. 2004, 66:89-96.
74. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., Catinari S., Ermilov M. d-Serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 2005, 57:577-585.
75. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Horowitz A., Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry 1996, 169:610-617.
76. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry 1999, 56:29-36.
77. Hurd R., Sailasuta N., Srinivasan R., Vigneron D.B., Pelletier D., Nelson S.J. Measurement of brain glutamate using TE-averaged PRESS at 3T. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 2004, 51:435-440.
78. Hutcheson N.L., Reid M.A., White D.M., Kraguljac N.V., Avsar K.B., Bolding M.S., Knowlton R.C., den Hollander J.A., Lahti A.C. Multimodal analysis of the hippocampus in schizophrenia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging. Schizophr. Res. 2012, 140:136-142.
79. 1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology 2006, 240:318-332.
80. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 1994, 151:1234-1236.
81. Jessen F., Fingerhut N., Sprinkart A.M., Kuhn K.U., Petrovsky N., Maier W., Schild H.H., Block W., Wagner M., Traber F. N-Acetylaspartylglutamate (NAAG) and N-acetylaspartate (NAA) in patients with schizophrenia. Schizophr. Bull. 2013, 39:197-205.
82. Jeste D.V., Twamley E.W., Eyler Zorrilla L.T., Golshan S., Patterson T.L., Palmer B.W. Aging and outcome in schizophrenia. Acta Psychiatr. Scand. 2003, 107:336-343.
83. Jeste D.V., Wolkowitz O.M., Palmer B.W. Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia. Schizophr. Bull. 2011, 37:451-455.
84. 1H MR spectroscopy study at 4T. Neurobiol. Aging 2005, 26:665-672.
85. Kaiser L.G., Young K., Matson G.B. Elimination of spatial interference in PRESS-localized editing spectroscopy. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 2007, 58:813-818.
86. Kaufman M.J., Prescot A.P., Ongur D., Evins A.E., Barros T.L., Medeiros C.L., Covell J., Wang L., Fava M., Renshaw P.F. Oral glycine administration increases brain glycine/creatine ratios in men: a proton magnetic resonance spectroscopy study. Psychiatry Res. 2009, 173:143-149.
87. 13C N.M.R. Biochem. J. 1994, 298(Pt. 1):121-127.
88. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
89. Kegeles L.S., Mao X., Stanford A.D., Girgis R., Ojeil N., Xu X., Gil R., Slifstein M., Abi-Dargham A., Lisanby S.H., Shungu D.C. Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 2012, 69:449-459.
90. Kelemen O., Kiss I., Benedek G., Keri S. Perceptual and cognitive effects of antipsychotics in first-episode schizophrenia: the potential impact of GABA concentration in the visual cortex. Progr. Neuropsychopharmacol. Biol. Psychiatry 2013, 47:13-19.
91. 1H MRS brain metabolite concentrations in vivo. Magn. Reson. Imaging 2003, 21:787-797.
92. Kraguljac N.V., Reid M.A., White D.M., den Hollander J., Lahti A.C. Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia. Neuropsychopharmacology 2012, 37:2635-2642.
93. Kraguljac N.V., White D.M., Reid M.A., Lahti A.C. Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry 2013, 70:1294-1302.
94. Lahti A.C., Weiler M.A., Tamara Michaelidis B.A., Parwani A., Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001, 25:455-467.
95. 2 relaxation study. J. Neurol. 2004, 251:284-293.
96. Lewis D.A., Curley A.A., Glausier J.R., Volk D.W. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012, 35:57-67.
97. Liang Z.-P., Lauterbur P.C. Principles of Magnetic Resonance Imaging: A Signal Processing Perspective 2000, SPIE Optical Engineering Press/IEEE Press, Bellingham, Washington, New York.
98. Lutkenhoff E.S., van Erp T.G., Thomas M.A., Therman S., Manninen M., Huttunen M.O., Kaprio J., Lonnqvist J., O'Neill J., Cannon T.D. Proton MRS in twin pairs discordant for schizophrenia. Mol. Psychiatry 2010, 15:308-318.
99. Maddock R. The problem of spurious correlations between pairs of brain metabolite values measured in the same voxel with magnetic resonance spectroscopy. JAMA Psychiatry 2014, 71:338-339.
100. Maddock R.J., Buonocore M.H. MR spectroscopic studies of the brain in psychiatric disorders. Curr. Top. Behav. Neurosci. 2012, 11:199-251.
101. Magistretti P.J., Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 1999, 354:1155-1163.
102. Marsman A., van den Heuvel M.P., Klomp D.W., Kahn R.S., Luijten P.R., Hulshoff Pol H.E. Glutamate in schizophrenia: a focused review and meta-analysis of (1)H-MRS studies. Schizophr. Bull. 2013, 39:120-129.
103. Mathews G.C., Diamond J.S. Neuronal glutamate uptake Contributes to GABA synthesis and inhibitory synaptic strength. J. Neurosci.: Off. J. Soc. Neurosci. 2003, 23:2040-2048.
104. 1H-MRS study. PLoS ONE 2008, 3:e1944.
105. Meador-Woodruff J.H., Clinton S.M., Beneyto M., McCullumsmith R.E. Molecular abnormalities of the glutamate synapse in the thalamus in schizophrenia. Ann. N. Y. Acad. Sci. 2003, 1003:75-93.
106. Mekle R., Mlynarik V., Gambarota G., Hergt M., Krueger G., Gruetter R. MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 2009, 61:1279-1285.
107. Mescher M., Merkle H., Kirsch J., Garwood M., Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 1998, 11:266-272.
108. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci.: Off. J. Soc. Neurosci. 1997, 17:2921-2927.
109. Mullins P.G., Chen H., Xu J., Caprihan A., Gasparovic C. Comparative reliability of proton spectroscopy techniques designed to improve detection of J-coupled metabolites. Magn. Reson. Med. 2008, 60:964-969.
110. Mullins P.G., McGonigle D.J., O'Gorman R.L., Puts N.A., Vidyasagar R., Evans C.J., Edden R.A. Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA. Neuroimage 2014, 86:43-52.
111. 1H-MRS measurements in schizophrenic patients. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 2003, 50:704-707.
112. Natsubori T., Inoue H., Abe O., Takano Y., Iwashiro N., Aoki Y., Koike S., Yahata N., Katsura M., Gonoi W., Sasaki H., Takao H., Kasai K., Yamasue H. Reduced frontal glutamate+glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia. Schizophr. Bull. 2014, 40(5):1128-1139.
113. Neale J.H., Olszewski R.T., Zuo D., Janczura K.J., Profaci C.P., Lavin K.M., Madore J.C., Bzdega T. Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family. J. Neurochem. 2011, 118:490-498.
114. Near J., Andersson J., Maron E., Mekle R., Gruetter R., Cowen P., Jezzard P. Unedited in vivo detection and quantification of gamma-aminobutyric acid in the occipital cortex using short-TE MRS at 3T. NMR Biomed. 2013, 26:1353-1362.
115. O'Donnell P. Adolescent onset of cortical disinhibition in schizophrenia: insights from animal models. Schizophr. Bull. 2011, 37:484-492.
116. O'Gorman R.L., Michels L., Edden R.A., Murdoch J.B., Martin E. In vivo detection of GABA and glutamate with MEGA-PRESS: reproducibility and gender effects. J. Magn. Reson. Imaging 2011, 33:1262-1267.
117. Olszewski R.T., Janczura K.J., Ball S.R., Madore J.C., Lavin K.M., Lee J.C., Lee M.J., Der E.K., Hark T.J., Farago P.R., Profaci C.P., Bzdega T., Neale J.H. NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia. Transl. Psychiatry 2012, 2:e145.
118. Olszewski R.T., Wegorzewska M.M., Monteiro A.C., Krolikowski K.A., Zhou J., Kozikowski A.P., Long K., Mastropaolo J., Deutsch S.I., Neale J.H. Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biol. Psychiatry 2008, 63:86-91.
119. Ongur D., Jensen J.E., Prescot A.P., Stork C., Lundy M., Cohen B.M., Renshaw P.F. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol. Psychiatry 2008, 64:718-726.
120. Ongur D., Prescot A.P., Jensen J.E., Cohen B.M., Renshaw P.F. Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res. 2009, 172:44-48.
121. Ongur D., Prescot A.P., McCarthy J., Cohen B.M., Renshaw P.F. Elevated gamma-aminobutyric acid levels in chronic schizophrenia. Biol. Psychiatry 2010, 68:667-670.
122. Otazo R., Tsai S.Y., Lin F.H., Posse S. Accelerated short-TE 3D proton echo-planar spectroscopic imaging using 2D-SENSE with a 32-channel array coil. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 2007, 58:1107-1116.
123. Petroff O.A., Mattson R.H., Rothman D.L. Proton MRS: GABA and glutamate. Adv. Neurol. 2000, 83:261-271.
124. Poels E.M., Kegeles L.S., Kantrowitz J.T., Javitt D.C., Lieberman J.A., Abi-Dargham A., Girgis R.R. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr. Res. 2014, 152:325-332.
125. Poels E.M., Kegeles L.S., Kantrowitz J.T., Slifstein M., Javitt D.C., Lieberman J.A., Abi-Dargham A., Girgis R.R. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol. Psychiatry 2014, 19:20-29.
126. Posse S., Otazo R., Dager S.R., Alger J. MR spectroscopic imaging: principles and recent advances. J. Magn. Reson. Imaging 2013, 37:1301-1325.
127. Pouwels P.J., Frahm J. Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. NMR Biomed. 1997, 10:73-78.
128. Prescot A.P., de B.F.B., Wang L., Brown J., Jensen J.E., Kaufman M.J., Renshaw P.F. In vivo detection of brain glycine with echo-time-averaged (1)H magnetic resonance spectroscopy at 4.0T. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 2006, 55:681-686.
129. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993, 30:672-679.
130. Provencher S.W. LCModel & LCMgui User's Manual 2014.
131. Purdon S.E., Valiakalayil A., Hanstock C.C., Seres P., Tibbo P. Elevated 3T proton MRS glutamate levels associated with poor continuous performance test (CPT-0X) scores and genetic risk for schizophrenia. Schizophr. Res. 2008, 99:218-224.
132. Raffa M., Mechri A., Othman L.B., Fendri C., Gaha L., Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Progr. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:1178-1183.
133. Ramadan S., Lin A., Stanwell P. Glutamate and glutamine: a review of in vivo MRS in the human brain. NMR Biomed. 2013, 26:1630-1646.
134. 1H short echo-time signals: background accommodation. Magma 2004, 16:284-296.
135. Reid M.A., Kraguljac N.V., Avsar K.B., White D.M., den Hollander J.A., Lahti A.C. Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia. Schizophr. Res. 2013, 147:348-354.
136. Reid M.A., Stoeckel L.E., White D.M., Avsar K.B., Bolding M.S., Akella N.S., Knowlton R.C., den Hollander J.A., Lahti A.C. Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol. Psychiatry 2010, 68:625-633.
137. Reynolds L.M., Reynolds G.P. Differential regional N-acetylaspartate deficits in postmortem brain in schizophrenia, bipolar disorder and major depressive disorder. J. Psychiatry Res. 2011, 45:54-59.
138. Rothman D.L., Sibson N.R., Hyder F., Shen J., Behar K.L., Shulman R.G. In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 1999, 354:1165-1177.
139. Rowland L., Bustillo J.R., Lauriello J. Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia. Semin. Clin. Neuropsychiatry 2001, 6:121-130.
140. Rowland L.M., Bustillo J.R., Mullins P.G., Jung R.E., Lenroot R., Landgraf E., Barrow R., Yeo R., Lauriello J., Brooks W.M. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am. J. Psychiatry 2005, 162:394-396.
141. Rowland L.M., Kontson K., West J., Edden R.A., Zhu H., Wijtenburg S.A., Holcomb H.H., Barker P.B. In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr. Bull. 2013, 39:1096-1104.
142. Rowland L.M., Spieker E.A., Francis A., Barker P.B., Carpenter W.T., Buchanan R.W. White matter alterations in deficit schizophrenia. Neuropsychopharmacology 2009, 34:1514-1522.
143. Ruiz-Litago F., Seco J., Echevarria E., Martinez-Cengotitabengoa M., Gil J., Irazusta J., Gonzalez-Pinto A.M. Adaptive response in the antioxidant defence system in the course and outcome in first-episode schizophrenia patients: a 12-months follow-up study. Psychiatry Res. 2012, 200:218-222.
144. 1H MR spectroscopy: strong coupling effects in vitro and in vivo. Magn. Reson. Imaging 1995, 13:853-869.
145. Schubert F., Gallinat J., Seifert F., Rinneberg H. Glutamate concentrations in human brain using single voxel proton magnetic resonance spectroscopy at 3Tesla. Neuroimage 2004, 21:1762-1771.
146. Seeger U., Klose U., Mader I., Grodd W., Nagele T. Parameterized evaluation of macromolecules and lipids in proton MR spectroscopy of brain diseases. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 2003, 49:19-28.
147. Shave E., Pliss L., Lawrance M.L., FitzGibbon T., Stastny F., Balcar V.J. Regional distribution and pharmacological characteristics of [3H]N-acetyl-aspartyl-glutamate (NAAG) binding sites in rat brain. Neurochem. Int. 2001, 38:53-62.
148. Shirayama Y., Obata T., Matsuzawa D., Nonaka H., Kanazawa Y., Yoshitome E., Ikehira H., Hashimoto K., Iyo M. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. Neuroimage 2010, 49:2783-2790.
149. Stagg C.J., Bestmann S., Constantinescu A.O., Moreno L.M., Allman C., Mekle R., Woolrich M., Near J., Johansen-Berg H., Rothwell J.C. Relationship between physiological measures of excitability and levels of glutamate and GABA in the human motor cortex. J. Physiol. 2011, 589:5845-5855.
150. Stagg C.J., Wylezinska M., Matthews P.M., Johansen-Berg H., Jezzard P., Rothwell J.C., Bestmann S. Neurochemical effects of theta burst stimulation as assessed by magnetic resonance spectroscopy. J. Neurophysiol. 2009, 101:2872-2877.
151. 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 2005, 30:1949-1962.
152. Stone J.M. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia. Curr. Pharm. Des. 2009, 15:2594-2602.
153. Stone J.M., Day F., Tsagaraki H., Valli I., McLean M.A., Lythgoe D.J., O'Gorman R.L., Barker G.J., McGuire P.K. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol. Psychiatry 2009, 66:533-539.
154. 1H-MRS: relationship to ketamine-induced psychopathology. Mol. Psychiatry 2012, 17:664-665.
155. Taylor S.F., Demeter E., Phan K.L., Tso I.F., Welsh R.C. Abnormal GABAergic function and negative affect in schizophrenia. Neuropsychopharmacology 2014, 39:1000-1008.
156. Tayoshi S., Nakataki M., Sumitani S., Taniguchi K., Shibuya-Tayoshi S., Numata S., Iga J., Ueno S., Harada M., Ohmori T. GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study. Schizophr. Res. 2010, 117:83-91.
157. 1H-MRS). Schizophr. Res. 2009, 108:69-77.
158. Terpstra M., Henry P.G., Gruetter R. Measurement of reduced glutathione (GSH) in human brain using LCModel analysis of difference-edited spectra. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 2003, 50:19-23.
159. Terpstra M., Ugurbil K., Gruetter R. Direct in vivo measurement of human cerebral GABA concentration using MEGA-editing at 7Tesla. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 2002, 47:1009-1012.
160. 1H NMR spectroscopy at 4T: application to schizophrenia. Magma 2005, 18:276-282.
161. Theberge J., Al-Semaan Y., Williamson P.C., Menon R.S., Neufeld R.W., Rajakumar N., Schaefer B., Densmore M., Drost D.J. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am. J. Psychiatry 2003, 160:2231-2233.
162. Theberge J., Bartha R., Drost D.J., Menon R.S., Malla A., Takhar J., Neufeld R.W., Rogers J., Pavlosky W., Schaefer B., Densmore M., Al-Semaan Y., Williamson P.C. Glutamate and glutamine measured with 4.0T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am. J. Psychiatry 2002, 159:1944-1946.
163. Theberge J., Williamson K.E., Aoyama N., Drost D.J., Manchanda R., Malla A.K., Northcott S., Menon R.S., Neufeld R.W., Rajakumar N., Pavlosky W., Densmore M., Schaefer B., Williamson P.C. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br. J. Psychiatry 2007, 191:325-334.
164. Tibbo P., Hanstock C., Valiakalayil A., Allen P. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am. J. Psychiatry 2004, 161:1116-1118.
165. Tsai S.J. Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia. Med. Sci. Monit. 2005, 11:HY39-HY45.
166. Valli I., Stone J., Mechelli A., Bhattacharyya S., Raffin M., Allen P., Fusar-Poli P., Lythgoe D., O'Gorman R., Seal M., McGuire P. Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis. Biol. Psychiatry 2011, 69:97-99.
167. Van Horn M.R., Sild M., Ruthazer E.S. d-Serine as a gliotransmitter and its roles in brain development and disease. Front. Cell Neurosci. 2013, 7:39.
168. Wijtenburg S.A., Gaston F.E., Spieker E.A., Korenic S.A., Kochunov P., Hong L.E., Rowland L.M. Reproducibility of phase rotation STEAM at 3T: Focus on glutathione. Magn. Reson. Med. 2014, 72:603-609.
169. 1H magnetic resonance spectroscopy. J. Magn. Reson. Imaging 2011, 34:645-652.
170. Winchester C.L., Pratt J.A., Morris B.J. Risk genes for schizophrenia: translational opportunities for drug discovery. Pharmacol. Ther. 2014, 143:34-50.
171. 1H-MRS investigation. Neurobiol. Dis. 2009, 33:354-357.
172. Wood S.J., Kennedy D., Phillips L.J., Seal M.L., Yucel M., Nelson B., Yung A.R., Jackson G., McGorry P.D., Velakoulis D., Pantelis C. Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study. Neuroimage 2010, 52:62-68.
173. Wood S.J., Yucel M., Wellard R.M., Harrison B.J., Clarke K., Fornito A., Velakoulis D., Pantelis C. Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3T. Schizophr. Res. 2007, 94:328-331.
174. Wroblewska B., Wegorzewska I.N., Bzdega T., Olszewski R.T., Neale J.H. Differential negative coupling of type 3 metabotropic glutamate receptor to cyclic GMP levels in neurons and astrocytes. J. Neurochem. 2006, 96:1071-1077.
175. Wroblewska B., Wroblewski J.T., Pshenichkin S., Surin A., Sullivan S.E., Neale J.H. N-Acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J. Neurochem. 1997, 69:174-181.
176. Wu G., Fang Y.Z., Yang S., Lupton J.R., Turner N.D. Glutathione metabolism and its implications for health. J. Nutr. 2004, 134:489-492.
177. Wu J.Q., Kosten T.R., Zhang X.Y. Free radicals, antioxidant defense systems, and schizophrenia. Progr. Neuropsychopharmacol. Biol. Psychiatry 2013, 46:200-206.
178. Yang S., Hu J., Kou Z., Yang Y. Spectral simplification for resolved glutamate and glutamine measurement using a standard STEAM sequence with optimized timing parameters at 3, 4, 4.7, 7, and 9.4T. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 2008, 59:236-244.
179. Yao J.K., Leonard S., Reddy R. Altered glutathione redox state in schizophrenia. Dis. Markers 2006, 22:83-93.
180. Yoon J.H., Maddock R.J., Rokem A., Silver M.A., Minzenberg M.J., Ragland J.D., Carter C.S. GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J. Neurosci.: Off. J. Soc. Neurosci. 2010, 30:3777-3781.
181. Yung A.R., McGorry P.D., McFarlane C.A., Jackson H.J., Patton G.C., Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr. Bull. 1996, 22:283-303.
182. Yung A.R., Yuen H.P., Berger G., Francey S., Hung T.C., Nelson B., Phillips L., McGorry P. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?. Schizophr. Bull. 2007, 33:673-681.
183. Zavitsanou K., Ward P.B., Huang X.F. Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia. Neuropsychopharmacology 2002, 27:826-833.
184. Zhang Y., Li S., Marenco S., Shen J. Quantitative measurement of N-acetyl-aspartyl-glutamate at 3T using TE-averaged PRESS spectroscopy and regularized lineshape deconvolution. Magn. Reson. Med.: Off. J. Soc. Magn. Reson. Med. Soc. Magn. Reson. Med. 2011, 66:307-313.
185. Zhu H., Barker P.B. MR spectroscopy and spectroscopic imaging of the brain. Methods Mol. Biol. 2011, 711:203-226.
186. Zuo D., Bzdega T., Olszewski R.T., Moffett J.R., Neale J.H. Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia. J. Biol. Chem. 2012, 287:21773-21782.